Value of PET-CT in Radiation Treatment Planning for Patients with Esophageal Cancer (RESPECT-study). - PET-CT radiotherapy planning in esophageal cancer

niversitair Medisch Centrum Groningen0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- histological documented cancer of the esophagus or gastroesophageal junction (GEJ)
•- locally curable disease without distant metastases (M1b is excluded)
•- planned for high dose radiotherapy with or without chemotherapy
•- no previous or concurrent malignancy (except for basal cell ca. of the skin or in situ ca. of the cervix or superficial bladder ca. (pTa) in the past five years.
•- previously untreated patients (except induction chemotherapy)
•- no evidence of serious active infections
•- no serious medical/psychiatric illness
•- age >= 18 years
•- written informed consent to participate in the study
•- patients must have an WHO performance status 0 - 2
•- all patients must be evaluated by a radiation oncologist prior to enrollment to ensure that the patient is an appropriate candidate for radiation therapy.
•- patients are required to have an adequate total caloric intake to allow them to maintain their body weight (stable weight or less than 2 pound weight loss) for at least one week prior to registration

•- patients with known distant metastases
•- previous or concurrent malignancy (except for basal cell carc of the skin or in situ ca. of the cervix or superficial bladder ca (pTa) in the past five years.
•- prior chest or upper abdomen radiotherapy, prior systemic chemotherapy, or prior esophageal or gastric surgery.
•- evidence of serious active infections
•- dementia or altered mental status that would prohibit the understanding and giving of informed consent
•- pregnant or lactating women. Sexually active patients of childbearing potential must implement effective contraceptive practices during the study while in this study

发起方